Home / Drug shortages / Travoprost Ophthalmic Solution

Travoprost Ophthalmic Solution — FDA Drug Shortage

To Be Discontinued — Mylan Pharmaceuticals Inc., a Viatris Company

The FDA lists a drug shortage record for Travoprost Ophthalmic Solution (ophthalmic solution) from Mylan Pharmaceuticals Inc., a Viatris Company with status To Be Discontinued. The shortage was first posted on 07/07/2026.

Shortage Details

Status
To Be Discontinued
Company
Mylan Pharmaceuticals Inc., a Viatris Company
Package NDC
0378-9651-32
Dosage Form
Ophthalmic Solution
Presentation
Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32)
Initial Posting
07/07/2026
Revised Date

FDA data resources